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Abstract
Background: The incidence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma
(OPSCC) has been rising in recent years. Given the clinical impact of HPV/p16 positivity in OPSCC, identifying
surrogate markers of this disease early in the diagnostic work-up of these patients could improve patient care.
Methods: Demographic, pathologic, staging and PET-CT data from patients diagnosed with OPSCC from 2009–2014
were obtained from a prospectively collected provincial cancer registry. Tumor HPV/p16 status was correlated to the
maximum standard uptake value (SUVmax) of the primary tumor and cervical nodes. Comparisons of means and
multinomial regression models were used to determine associations between p16 status and SUVmax. A diagnostic odds
ratio was calculated using a cut off value for predicting HPV/p16 positivity based on nodal SUVmax.
Results: PET-CT and HPV/p16 data was obtained for 65 patients treated surgically for OPSCC. Significantly higher nodal
SUVmax was associated with HPV/p16 positive nodes (SUVmax 10.8 vs 7.9). No significant differences were seen between
HPV/p16 positive vs negative primary tumor SUVmax (10.3 vs 13.7). In combination with other clinical parameters, higher
nodal SUVmax was highly correlated with HPV/p16 positivity.
Conclusion: Elevated nodal SUVmax is a significant predictor of HPV/p16 positive disease.
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Introduction
Oropharyngeal squamous cell carcinoma (OPSCC) is an
aggressive malignancy with a rising incidence worldwide
[1–3]. Oncogenic human papillomavirus (HPV) infec-
tion, tobacco and alcohol are well established etiological
factors for OPSCC [4, 5]. A large body of evidence from
recent years has demonstrated that HPV positive and
negative OPSCC are distinct from clinical, pathological
and molecular perspectives [4, 6–12]. Most importantly;
patients with HPV-related OPSCC, generally pathologic-
ally identified by p16 positivity, have favorable survival
outcomes following both surgical and non-surgical
treatment approaches [4, 5, 13]. As recommended by
recent head and neck cancer treatment guidelines, it is
important to establish a pathologic diagnosis of HPV/
p16 OPSCC for purposes of prognostication [14]. Des-
pite well-characterized clinical and histopathological
differences, the treatment algorithm for HPV/p16 posi-
tive and negative OPSCC remains unchanged.
Positron emission tomography-computed tomography
(PET-CT) is an important tool for the diagnosis and
surveillance of OPSCC [12, 15, 16]. PET-CT utilizes glu-
cose metabolism to identify tumor metabolic activity,
which can accurately identify locoregional disease better
than CT alone, particularly in smaller nodes [17, 18].
Rates of cervical lymph node metastases in HPV positive
OPSCC have been reported to be 60-76 % at initial
presentation [19]. Sensitivity and specificity of detecting
cervical node metastases with PET-CT is high, ranging
from 84-92 % and 95-99 %, respectively [18]. HPV
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positive nodal metastases often present as a cystic or
necrotic neck mass which may be less metabolically
active on PET [20]. Additionally, inflammatory nodes
can present as FDG avid lymphadenopathy and could
represent false positives on PET imaging. Combining
PET with CT allows for precise anatomic localization
and further characterization of these potential metastatic
lymph nodes.
The clinical role of PET-CT to localize primary tumors
and metastatic disease has been well-established; but
researchers are continuing to try to identify specific
imaging biomarkers that may help diagnose, provide
information about prognosis and guide treatments for
patients with OPSCC. Maximum standard uptake value
(SUVmax) is a quantitative measure of the highest FDG
uptake within the region of interest. It has been hypothe-
sized by others that a high SUVmax would be associated
with a poor outcome, reflecting the increased proliferation
of the tumor cells [21]. However HPV positive tumors,
known to have favorable outcomes, are thought to have
higher metabolic activity with increased proliferation and
a predilection for early metastasis [22, 23]. Recent data
from Kendi et al. [24] support the hypothesis that higher
SUVmax is associated with HPV/p16 positivity. There is
therefore conflicting evidence regarding the association
between SUVmax and HPV/p16 positivity in OPSCC
[21, 24–26]. To this end, we aimed to determine the
correlation between nodal SUVmax and p16 status of
OPSCC tumors using a cohort of patients treated with
primary surgery.
Methods
The University of Alberta Research Ethics Board granted
ethics approval for the study (Pro00016426).
Patients
Patients were identified using a prospectively collected
database (Alberta Cancer Registry [27] (ACR)) of patients
treated for OPSCC from January 2009 – December
2014 at a tertiary cancer treatment facility in Alberta,
Canada. All adult patients treated with a primary
surgical approach with a pre-treatment PET-CT and
p16 status of the OPSCC were included within the
cohort (Fig. 1). Patients were categorized as smokers
using a previously defined cutoff of ≥ 10 pack years
of tobacco use [4]. Patients were excluded if they
had received previous treatment for head and neck
cancer or found to have an N0 neck on surgical
pathology. Initial demographic information was ob-
tained from the ACR and verified by retrospective re-
view of patients’ charts. HPV-status was obtained by
immunohistochemistry staining for p16, a surrogate
marker of oncogenic HPV, as previously reported
using established standards [11, 13, 28, 29].
PET-CT image analysis
PET-CT protocols were obtained using two scanners, both
Gemini TF 16-slice PET-CT scanner systems (Phillips
Healthcare, Andover, MA). All patients were scanned with
a consistent head and neck protocol. Following a fasting
period of at least 4 h and serum baseline glucose measure-
ments, patients were injected with 5.18 MBq/kg of 18-
FDG tracer. A minimum of 60 min was waited following
tracer injection and PET scanning. Two separate acquisi-
tions were used to scan patients from skull vertex to mid
thighs. Following the PET scan, patients were injected
with intravenous contrast and a helical CT was performed
to scan patients from skull vertex to mid thighs.
Using OASIS software (Segami Corporation, Columbus,
Ohio), PET-CT images were reviewed by authors JC, CJ
and TC. Reviewers were blinded to p16 status at the time
of imaging review. Coronal, sagittal and transverse images
were examined to identify SUVmax of the primary tumor
and cervical nodal metastases. A spherical volumetric area
of interest was focused upon individual lesions in the head
and neck to identify metabolic parameters of the lesions.
Final radiological and nuclear medicine reports were
reviewed for additional correlation of findings. Only nodal
and primary malignancies with FDG uptake were included
within the analysis. The SUVmax for the primary as well
as the nodal SUVmax were obtained from the OASIS soft-
ware. In patients with multiple FDG avid cervical lymph
nodes, the highest SUVmax was recorded, consistent with
previous PET-CT protocols [25].
Statistical analyses
SPSS version 23.0 was used for statistical analyses (SPSS
Inc., Chicago, IL, USA). Regression analyses of factors
and covariates were performed to include age, gender,
TNM staging, tumor subsite, treatment, smoking status,
p16 positivity and SUVmax. ANOVA, Mann Whittney U
Fig. 1 Inclusion and exclusion criteria. OPSCC – oropharyngeal
squamous cell carcinoma, CRT – chemoradiation, PET-CT – positron
emission tomography – computed tomography, N0 – no nodal disease.
Patients who were treated with initial surgical resection and neck
dissection +/− radiation/chemoradiation were considered to have
primary surgical treatment
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test, and the Kruskal-Wallis test were used to calculate
differences between groups where appropriate. Statistical
significance was defined as p < 0.05.
Results
A prospectively collected database identified 167 pa-
tients who were treated at the University of Alberta for
OPSCC between 2009 and 2014. Of the patients treated
with primary surgery, sixty-five had adequate pre-
treatment PET-CT and p16 status available (Fig. 1).
Patients with p16 negative disease were more likely to
have a smoking history (>10 pack years) (Table 1). No
statistically significant differences were seen between
p16 positive and negative patients in terms of age at
presentation, gender, T stage and N stage.
The mean SUV max of the primary tumor for p16
negative disease (13.7) was higher than that for p16
positive disease (10.3) but there was no significant dif-
ference when these were assessed with a Mann Whit-
ney U comparison of means (p = 0.28). The average
nodal SUVmax for p16 positive disease (10.8) was
significantly higher (p = 0.02) than that for p16 negative
disease (7.9) (Fig. 2).
Using the dependent variable, p16 status, a multi-
nomial logistic regression analysis was performed
(Table 2). The only variable that was found to be signifi-
cant in predicting p16 status was nodal SUVmax. Higher
nodal SUVmax was associated with p16 positive disease.
Primary tumor SUVmax was not a significant predictor.
Using the mean SUVmax of p16 positive nodes as a
significant predictor of p16 positive disease, we cate-
gorized patients according to this cutoff value (mean
SUVmax p16+). Patients with nodal SUVmax ≥mean
SUVmax p16+ had a positive predictive value of p16 posi-
tive disease of 92.3 %. The diagnostic odds ratio (DOR) of
the mean SUVmax p16+ was 4.9 (95 % CI, 1.0-24.3)
Discussion
The emergence of PET-CT as a diagnostic tool for head
and neck malignancies has allowed physicians to identify
primary tumors and locoregional metastases early in the
disease course. Many feel the role of PET-CT can be
expanded to help characterize some of these lesions to
more accurately diagnose and target therapy for different
types of cancers. This study has shown a significant asso-
ciation between higher nodal SUVmax and p16 positive
disease status. In addition, in patients who had a nodal
SUVmax of greater than 10.8 (mean SUVmax p16+), we
could reliably predict p16 positive disease (DOR = 4.9). A
biological basis for these findings could represent the
higher cell division and oxygenation of p16 positive
tumors or the immune response of HPV infected nodes,
which could FDG activity [24].
Table 1 Demographics and staging of oropharyngeal
malignancies
Characteristic P16+ P16- P value
Age (mean, SD) 57.6, 7.6 59.5, 10.6 0.39
Gender (% male) 88.2 76.9 0.06
Smoking 54.9 84.6 < 0.001
Tumor stage









Fig. 2 Comparison of means for p16 positive and negative disease for primary and nodal maximum standard uptake value (SUVmax)
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Two similar studies examining the association of PET-
CT and HPV status have found conflicting results [24, 25].
Tahari and colleagues had a large cohort (N = 123) and
retrospectively examined the relationship between PET-
CT imaging markers and HPV status [25]. They found
higher PET values in HPV positive nodal metastasis but
this difference was not statistically significant. Kendi and
colleagues [24] examined the relationship of PET-CT
imaging markers and p16 status in patients with oral
cavity and OPSCC . Consistent with results from our
study, they found a statistically significantly higher nodal
SUVmax, but not primary tumor SUVmax, in patients
with HPV positive disease as compared to those with
HPV negative cancer. Although their study had a relatively
small sample size (N = 22), they also identified a nodal
SUVmax cut off value, which was predictive of HPV posi-
tivity (SUVmax >7.66). Our study supports a significant
association between p16 status and nodal SUVmax. With
this data, clinicians may be able to more accurately predict
HPV status based on imaging in combination with other
clinical parameters.
HPV positive tumors are being found in a new
population – younger males without environmental risk
factors such as tobacco and alcohol. Clinicians; however,
may be slow to screen these individuals for malignancies,
as they do not have the traditional exposures that have
been historically associated with head and neck cancer. As
a result, the average time for diagnosis of OPSCC is greater
than 3 months from initial presentation at a general prac-
tioner’s office [30]. Given the prognostic importance of p16
positivity in OPSCC, diagnostic information that can assist
in triaging patients according to p16 status is valuable to
both patients and physicians.
PET-CT also plays a role in identifying primary tumors
in cases of cancer of unknown primary (CUP). Multiple
studies have found HPV positive metastatic neck nodes
are more likely to be associated with an oropharyngeal
primary than other head and neck malignancies [31, 32].
Nodal SUVmax, identified on pre-treatment PET-CT
could give additional information about the underlying
malignancy for CUP. Having a high suspicion for p16
positive OPSCC based on imaging could help direct a
more aggressive search for a CUP. Recent reports using
transoral resection of base of tongue and tonsils in p16
positive CUPs have been >90 % effective in identifying
the primary site [33, 34].
Our findings could have a particularly useful clinical im-
plication in the diagnosis of OPSCC patients when surgi-
cal biopsy under general anesthesia may portend a high
risk of morbidity. If imaging with PET-CT could help
identify p16 status, clinicians may be able to tailor chemo-
radiation therapy in this population. It is thought the im-
proved prognosis of HPV positive OPSCC relates in part
to the increased radiosensitivity of the tumor. Currently
HPV positive and negative tumors are treated equivocally.
Given the variable pathologic and molecular behavior of
HPV positive and negative tumors, targeted treatments
may soon be developed that could allow for individualized
therapies that may reduce overall radiation-related side
effects and improve post-treatment quality of life.
This study has a number of limitations. Although
initial data were collected prospectively, it remains a
retrospective analysis in a single institution, which could
limit the generalizability of the results. As shown in
Fig. 1, several patients were excluded from the analysis
due to lack of PET-CT or p16 status, which could bias
our results. PET-CT protocols may vary between cancer
treatment facilities, which may limit the extrapolation of
nodal SUVmax cutoff values described herein. Finally, a
relatively small patient cohort was used in this analysis.
These limitations could be improved with further studies
using prospective data from multiple institutions.
Conclusions
There is a significant association between p16 positivity
and increased nodal SUVmax in OPSCC. Further larger
scale studies involving other institutions would be recom-
mended to examine the clinical utility of this association.
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